Program
amivantamab
Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.
Drug pageAmivantamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 1512 open or running | phase 3since Jul 23, 2020 | Nov 18, 2015 | Dec 31, 2026phase 1 · NCT02609776 |
| AstraZeneca | 11 open or running | phase 2since Mar 24, 2023 | Mar 24, 2023 | Oct 1, 2027phase 2 · NCT05801029 |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2019Named amivantamabINNProposed as its International Nonproprietary Name in WHO's List 121
- Mar 24, 2023First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
Ahead
- Oct 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05801029
TargetBeta
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
The one study AstraZeneca leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more | 2 | Active, not recruiting | Oct 1, 2027 | 60 |
How it is read
Names in the registry
- “Amivantamab”, 15 entries
- “Amivantamab IV”, 2 entries
- “Amivantamab SC”, 1 entry
- “Amivantamab Intravenous”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Colorectal Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Carcinoma, Hepatocellular, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.